372159-76-7

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a building block in the synthesis of pharmaceutical compounds for its versatile chemical properties and reactivity in organic synthesis.
Used in Organic Synthesis:
3-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the preparation of various organic chemicals, leveraging its ability to undergo a range of chemical reactions to form diverse molecular structures.

InChI:InChI=1/C12H21NO3/c1-12(2,3)16-11(15)13-7-4-5-10(9-13)6-8-14/h8,10H,4-7,9H2,1-3H3

Upstream product

• 146667-84-7 tert-butyl 3-(2-hydroxyethyl)-1-piperidinecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 948015-72-3 tert-butyl 3-(cyanomethyl)piperidine-1-carboxylate 
• 162166-99-6 3-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 4606-65-9 3-(hydroxymethy)piperidine 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 73579-06-3 3-(2-hydroxyethyl)piperidine 

Relevant academic research and scientific papers

NOVEL HISTONE METHYLTRANSFERASE INHIBITORS

The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

Pyridine derivatives

Pyridine compounds of general formula: wherein —R1represents in which R11is hydrogen, C1-6alkyl, halogen, hydroxy, C1-12alkoxy, nitro, amino, C1-6alkylsulfonylamino, C1-6alkoxycarbonyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkanoylamino, phenyl C1-6alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2represents hydrogen or halogen; R3represents hydrogen, —CR31R32R33, or —NR34R35; R4is hydrogen, carbamoyl, CN, carboxyl, etc.; R5is amino, C1-6alkylamino, di C1-6alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.

CCR3 antagonist leads with IC(50) values in the microM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC(50) values for CCR3.